What we do

WE ARE CONTRIBUTING TO THE RAPIDLY EXPANDING ENTREPRENEURSHIP ECOSYSTEM WITHIN PRINCETON UNIVERSITY. 

Developing scientifically-driven due diligence and venture creation materials

Mentorship and interaction from leaders in the biopharmaceutical industry

Traveling to biopharma investors and companies to pitch our work to refine our methodologies and organization

What We’ve Achieved

  • Sept. 2018: Established Alimtas Bioventures as a subteam of the Princeton Entrepreneurship Club and recruited five other members

  • Sept. 2018: Formed a partnership with the Princeton Office of Technology Licensing to spin out Princeton University life science discoveries

  • Oct. 2018: Formed a partnership with the New Jersey Health Foundation for strategic support

  • Nov. 2018: Started work on our first commercialization case. Working with Professor Schwartz and his Smart Scaffolding technology for tissue repair

  • May 2019: Pitch of our first case to Princeton community and local partners

  • June 2019: Trip to Chicago to pitch to Arch Ventures

  • Sept 2019: Begin working on our second commercialization case. Working with Prof Ploss and his Hepatitis B therapeutics technology.

  • Dec 2020: Trip to San Francisco to pitch to Arch Ventures, 5AM Ventures, Gilead, Genentech, and the Gladstone Institute

  • Sept 2020: Begin working on our third commercialization case. Working with Prof Ploss and his COVID-19 model for HTS.

  • Dec. 2020 — Feb. 2021: Virtually pitched to 5AM Ventures, Ginkgo Bioworks, Amgen, Genentech, Gilead Sciences, Vir Biotechnology, Merck & Co, and LianBio

  • Feb. 2021: Started work on our fourth commercialization case. Working with Prof Engel and his AAV therapeutics technology

  • Sept 2021: Started work with Professors Prud’homme and Hejazi doing background and market research for Optimeos Life Sciences

  • Feb 2022: Started work on our sixth commercialization case. Working with Professor Cohen on his electrotaxis-based wound healing technology

  • Apr 2022: Trip to Boston to pitch to Trinity Life Sciences and Atlas Venture

  • Sept 2022: Start work on our seventh commercialization case with Professor Seyedsayamdost and his novel antibiotics approach.

  • March 2023: Trip to San Francisco to pitch Crx-1k to Arch Ventures, Trinity Life Sciences, Gladstone, MPM Capital, and Genentech.